Area of research
Molecular Medicine · Pharmacology
Research interest
Research interests include Antibiotic Resistance in Bacteria, Antibiotics Pharmacokinetics and Efficacy, Bacterial Identification and Susceptibility Testing, and Bacterial biofilms and quorum sensing.
Disarming carbapenemase-producing <i>Acinetobacter baumannii</i>: high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310).
Emergence of KPC-producing <i>Pseudomonas aeruginosa</i> in Spain: insights into an outbreak and resistance to the novel carbapenem/β-lactamase inhibitor combinations imipenem/relebactam and meropenem/vaborbactam.
Antibacterial activity of enmetazobactam against <i>Acinetobacter</i> spp.: a molecular dissection of mechanism of action and resistance determinants.
<i>Pseudomonas aeruginosa</i> Vaccine Development: Lessons, Challenges, and Future Innovations.
Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitors.
Multicenter evaluation of Fourier transform infrared (FTIR) spectroscopy as a first-line typing tool for carbapenemase-producing <i>Klebsiella pneumoniae</i> in clinical settings.
The novel polymyxin analogue SPR206 exhibits higher activity than colistin against both colistin-susceptible and colistin-resistant strains of <i>Acinetobacter baumannii</i>.
Functional and structural analyses of amino acid sequence variation in PDC β-lactamase reveal different mechanistic pathways toward cefiderocol resistance in <i>Pseudomonas aeruginosa</i>.
Contribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility in <i>Pseudomonas aeruginosa</i>.
Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations.
Analysis of high-molecular-weight proteins using MALDI-TOF MS and machine learning for the differentiation of clinically relevant Clostridioides difficile ribotypes.
Engineering and Evaluation of a Live-Attenuated Vaccine Candidate with Enhanced Type 1 Fimbriae Expression to Optimize Protection Against <i>Salmonella</i> Typhimurium.
In Vitro Susceptibility to Imipenem/Relebactam and Comparators in a Multicentre Collection of <i>Mycobacterium abscessus</i> Complex Isolates.
Rapid prediction of carbapenemases in <i>Pseudomonas aeruginosa</i> by imipenem/relebactam and MALDI-TOF MS.
The multispecies microbial cluster of Fusobacterium, Parvimonas, Bacteroides and Faecalibacterium as a precision biomarker for colorectal cancer diagnosis.
Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial.
Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.
Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa.
<i>In vitro</i> activity of cefiderocol against European <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter</i> spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations.
The Challenge of Treating Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria: A Narrative Review.
Deciphering mechanisms affecting cefepime-taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain.
<i>In vitro</i> activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recentβ-lactam/β-lactamase inhibitor combinations.
Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales.
Epidemiology, resistance genomics and susceptibility of <i>Acinetobacter</i> species: results from the 2020 Spanish nationwide surveillance study.
Parvimonas micra can translocate from the subgingival sulcus of the human oral cavity to colorectal adenocarcinoma.
Emergence of Carbapenemase Genes in Gram-Negative Bacteria Isolated from the Wastewater Treatment Plant in A Coruña, Spain.
Activity and resistance mechanisms of the third generation tetracyclines tigecycline, eravacycline and omadacycline against nationwide Spanish collections of carbapenemase-producing Enterobacterales and Acinetobacter baumannii.
Mutant prevention concentrations, <i>in vitro</i> resistance evolution dynamics, and mechanisms of resistance to imipenem and imipenem/relebactam in carbapenem-susceptible <i>Klebsiella pneumoniae</i> isolates showing ceftazidime/avibactam resistance.
Real-world performance of susceptibility testing for cefiderocol: insights from a prospective multicentre study on Gram-negative bacteria.
Impact of transferable β-lactamases and intrinsic AmpC amino acid substitutions on the activity of cefiderocol against wild-type and iron uptake-deficient mutants of Pseudomonas aeruginosa.